|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Outsourcing Strategies: Market Expansion, Offshoring and Strategic Management in the CRO and CMO Marketplace
Business Insights, April 2006, Pages: 160
Over the last decade outsourcing has become an important strategic issue for pharmaceutical companies; rising pressure to reduce costs and time-to-market has led to outsourcing not only of traditional non-core functions such as manufacturing and clinical trials, but also increasingly of technically demanding areas such as drug discovery and biotech R&D.
Pharmaceutical Outsourcing Strategies is a new report which provides a comprehensive and up to date review of contract research and manufacturing, in addition to key strategies for pharmaceutical companies to optimize their relationships with contractors. Emerging trends are evaluated and offshore outsourcing opportunities are analyzed in the rapidly growing markets of Eastern Europe, China and India.
Use this report ’s best practice case studies and unique examination of future outsourcing trends -including cutting edge technologies and novel contract alliances to ensure that you implement the optimal strategies for your company ’s needs.
Key findings of the report...
- Although Eastern Europe possessed the most established infrastructure for outsourcing in 2005, the local pharmaceutical industries in India and China are growing quickly and over the next five years, are expected to account for a significantly greater portion of both contract research and contract manufacturing work.
- In recent years, the portfolio of services offered by CROs has widened dramatically to include R&D enabling technologies (e.g. drug discovery, genomics, high throughput screening, combinatorial chemistry) using proprietary techniques for which they often own the intellectual property rights. Portfolios may also include post-commercialization services such as contract sales and marketing.
- CROs are now seeking new revenue opportunities by entering into partnering relationships with sponsors in which they share the risk and rewards of developing a particular product. (PPDI case study)
- In quickly-changing and highly technology-dependent areas like drug discovery and biotechnology, costs are considerably higher for drug developers to establish state-of-the-art facilities in-house, therefore, outsourcing is often less expensive.
Key questions answered in this report
- What are the associated advantages and disadvantages of using CRO’s and CMO’s?
- What new portfolio of services are CRO’s now providing?
- What are the emerging fields in the pharmaceutical outsourcing market?
- How are sponsors minimizing relationship risks with contractors?
- Why outsource manufacturing and risk costly technology transfer delays?
- How are smaller CROs now competing with larger, full service groups?
- How is eTechnology being applied by CRO’s and CMO’s to reduce time and cost?
Top five reasons to order your copy today
- Critically assess offshore outsourcing in Eastern Europe, India and China, focusing on key current issues such as patent protection and related legislative changes.
- Analyze best practice outsourcing strategies undertaken by the industry’s key players including Wyeth, Novartis and GlaxoSmithKline and ensure that you implement these into your future processes.
- Integrate into your outsourcing processes strategies to mitigate a range of IP, confidentiality, financial, performance risks associated with using research and manufacturing contractors.
- Understand how eTechnologies such as internet based patient recruitment and electronic data capture will enable you to reduce the time and cost associated with drug discovery and increase the data integrity of clinical trials.
- Understand how Pharmaceutical Contract Research Alliances (PCRA’s) are enabling niche contractors to compete more effectively with large full service CRO’s.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
